A review of bioanalytical methods for chronic lymphocytic leukemia drugs and metabolites in biological matrices

Suresh, P S; Trivedi, Ravi; Srinivas, Nuggehally R.; Mullangi, Ramesh

doi:10.1002/bmc.4742

Cited by 4 publications

(2 citation statements)

References 103 publications

(199 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2020, a comprehensive review regarding analytical methods for determination of lymphocytic anti-leukaemia drugs, including sorafenib and nilotinib has been published by Suresh et al [19]. Bioanalysis of these compounds is gaining more and more interest.…”

Section: Introductionmentioning

confidence: 99%

Quantitative Analysis of Sorafenib and Nilotinib in Human Plasma by Spe-Lc-MS

POPESCU

2023

FARMACIA

View full text Add to dashboard Cite

Sorafenib and nilotinib are two tyrosine kinase inhibitors (TKIs) used in the treatment of cancer. Plasmatic levels of the drugs show an important variability, so determining plasma concentration of the drugs, benefits in cancer treatment can be improved. Most papers published so far in the literature use protein precipitation followed by liquid chromatographytandem mass-spectrometry (LC-MS/MS) as separation and detection method. With this work, we propose an alternative method for the analysis of both TKIs in human plasma. Solid phase extraction (SPE) involving Oasis PRiME HLB ® cartridges was our choice for plasma "clean-up" procedure. Extraction recoveries were at least 85%. Chromatography was performed by an ultra-high-performance liquid chromatographic system (UHPLC), using a C18 (4.6 x 50 mm) column and a mobile phase consisting of ammonium acetate/acetic acid-acetonitrile gradient elution. Detector was a simple mass spectrometer (MS) in Single Ion Recording (SIR) mode. Intra-and inter-day precision data for both TKIs were 3.8 -7.6% and 4.5 -8.8% for sorafenib and nilotinib, respectively. Sorafenib and nilotinib calibration curves were linear between 500 and 20000 ng/mL and 5 and 5000 ng/mL respectively, with correlation coefficients higher than 0.998. Analytes were determined in a 15 min run-time. The validated LC-MS method was applied in real human plasma routine analysis. This method may improve dose adjustment of the drugs in patients involved in cancer therapy. RezumatSorafenib și nilotinib sunt doi inhibitori ai tirozin kinazei utilizați în tratamentul cancerului. Nivelurile lor plasmatice prezintă o variabilitate importantă, astfel încât determinarea concentrațiilor lor, poate ajuta în tratamentul cancerului. Majoritatea articolelor din literatură utilizează precipitarea proteinelor ca metodă de pregătire a probelor și cromatografia de lichide și spectrometria de masă în tandem (LC-MS/MS) ca metodă de separare și detecție. Propunem o metodă alternativă pentru analiza ambelor medicamente în plasma umană. Extracția pe fază solidă (SPE) cu cartușe Oasis PRiME HLB ® a fost alegerea noastră pentru procedura de "curățare" a plasmei. Recuperările la extracție au fost de cel puțin 85%. Separarea a fost efectuată pe un cromatograf de lichide cu o coloană C18 (4,6 x 50 mm) și o fază mobilă cu gradient de eluție constând din acetat de amoniu/acid acetic-acetonitril. Detectorul a fost un spectrometru de masă (MS) în modul Single Ion Recording (SIR). Datele pentru precizia intra-și inter-zi pentru ambele TKI au fost 3,8 -7,6% și respectiv, 4,5 -8,8%. Curbele de calibrare pentru sorafenib și nilotinib au fost liniare între 500 și 20000 ng/mL și respectiv 5 și 5000 ng/mL, cu coeficienți de corelare mai mari de 0,998. Analiții au fost determinați într-un timp de 15 min. Metoda LC-MS a fost aplicată în analiza pe probe reale de plasmă. Această metodă poate îmbunătăți ajustarea dozei de medicamente la pacienții implicați în terapia anti-cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Quantitative Analysis of Sorafenib and Nilotinib in Human Plasma by Spe-Lc-MS

POPESCU

2023

FARMACIA

View full text Add to dashboard Cite

show abstract

“…Some old or recent reviews dealing with the literature reporting contributions to the derivatization for HPLC with specified detections (Higashi & Ogawa, 2016;Santa, 2011Santa, , 2013 may complete the present review. Reviews dedicated to the bioanalytical methods including derivatization for certain compounds are also available in the recent literature (Batra & Bhushan, 2018a, 2018bHancu, Lupu, Milan, Budau, & Barabas-Hajdu, 2020;Jia & Bartlett, 2020;Knikman, Rosing, Guchelaar, Cats, & Beijnen, 2020;Suresh, Trivedi, Srinivas, & Mullangi, 2020). Apecial attention was given to the bioanalysis of anticancer drugs, to which a very recent review has been dedicated that includes HPLC methods based on chemical derivatization (Sabourian et al, 2020).…”

mentioning

confidence: 99%

Derivatization procedures and their analytical performances for HPLC determination in bioanalysis

David

Moldoveanu

Galaon

2020

Biomedical Chromatography

View full text Add to dashboard Cite

Derivatization, or chemical structure modification, is often used in bioanalysis performed by liquid chromatography technique in order to enhance detectability or to improve the chromatographic performance for the target analytes. The derivatization process is discussed according to the analytical procedure used to achieve the reaction between the reagent and the target compounds (containing hydroxyl, thiol, amino, carbonyl and carboxyl as the main functional groups involved in derivatization). Important procedures for derivatization used in bioanalysis are in situ or based on extraction processes (liquid-liquid, solid-phase and related techniques) applied to the biomatrix. In the review, chiral, isotope-labeling, hydrophobicity-tailored and post-column derivatizations are also included, based on representative publications in the literature during the last two decades. Examples of derivatization reagents and brief reaction conditions are included, together with some bioanalytical applications and performances (chromatographic conditions, detection limit, stability and sample biomatrix).

show abstract

In Silico Study, Protein Kinase Inhibition and Molecular Docking Study of Benzimidazole Derivatives

Karthick,

Abishek,

Angel Jemima

2024

Bioinform Biol Insights

View full text Add to dashboard Cite

Kinase enzymes play an important role in cellular proliferation, and inhibition of their activity is a major goal of cancer therapy. Protein kinase inhibitors as benzimidazole derivatives can be applied for prevention or treatment of cancers through inhibition of cell proliferation. To evaluate their protein kinase inhibitory effects, as well as the in silico study for active benzimidazole derivatives. Benzimidazole derivatives has presented significant therapeutic potential against several disorders and known to have numerous biological activities (such as antibacterial, antiviral and anti-inflammatory). Benzimidazole derivatives have shown significant potential in the reduction of viral load as well as in enhancing immunity. To forecast absorption, distribution, metabolism, excretion and toxicity, simply known as ADMET and the Lipinski rule of five parameters of the examined substances, the admetSAR and Swiss ADME were used. The ADMET predictions revealed that the compounds had good and safe pharmacokinetic features, making them acceptable for further development as therapeutic candidates in clinical trials. This study primarily focused on blocking 2 key targets of kinase proteins (CDK4/CycD1 and Aurora B). 2-Phenylbenzimidazole has shown the greatest inhibitory potential (with a binding energy of −8.2 kcal/mol) against protein kinase inhibitors. This study results would pave the potential lead medication for anticancer therapeutic strategies.

show abstract

A review of bioanalytical methods for chronic lymphocytic leukemia drugs and metabolites in biological matrices

Cited by 4 publications

References 103 publications

Quantitative Analysis of Sorafenib and Nilotinib in Human Plasma by Spe-Lc-MS

Quantitative Analysis of Sorafenib and Nilotinib in Human Plasma by Spe-Lc-MS

Derivatization procedures and their analytical performances for HPLC determination in bioanalysis

In Silico Study, Protein Kinase Inhibition and Molecular Docking Study of Benzimidazole Derivatives

Contact Info

Product

Resources

About